Literature DB >> 3314311

Immunohistological study of mononuclear cell infiltrate in malignant gliomas.

M L Rossi1, J T Hughes, M M Esiri, H B Coakham, D B Brownell.   

Abstract

Sixty-five malignant gliomas (astrocytomas grade 3 and 4 and glioblastomas) were examined by means of immunoperoxidase staining on frozen tissue using various monoclonal antibodies directed against macrophages, lymphocytes and natural killer cells. Depending on the antibody used, the presence of macrophages in tumours ranged from 85%-100%. Many of the tumours contained substantial numbers of macrophages not only, as expected, in necrotic areas but also in intact tumour tissue. Eighty-nine percent of 39 tumours tested contained Fc receptor-bearing mononuclear cells in viable tumour. In 100% of 44 tumours tested for HLADR class 2 major histocompatibility complex antigen this antigen was detected in the macrophages. In 40% of these 44 cases, HLADR antigen was also present on the tumour cells. Eighty-eight percent of 53 tumours tested contained T cells in viable tumour and the majority of these cells were T cytotoxic/suppressor (T8). Twenty-four percent of 33 tumours contained no T helper/inducer (T4) lymphocytes and in the other 76% there were few positive cells. Only 9% of 21 tumours contained natural killer cells (NK). B cells were absent from 88% of 61 tumours and almost all of the remainder contained only a small number of B cells. The findings are discussed with reference to a possible host immune response to gliomas and relevant literature is reviewed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3314311     DOI: 10.1007/BF00688191

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  41 in total

1.  Immunohistologic evaluation of the lymphoreticular infiltrate of human central nervous system tumors.

Authors:  G W Wood; R A Morantz
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

2.  Role of nominal antigen and Ia antigen in the binding of antigen-specific T lymphocytes to macrophages.

Authors:  O Werdelin; E M Shevach
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

3.  Factor-induced differentiation and activation of macrophages.

Authors:  N Hogg
Journal:  Immunol Today       Date:  1986-03

4.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

5.  Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells.

Authors:  S Carrel; N De Tribolet; N Gross
Journal:  Eur J Immunol       Date:  1982-04       Impact factor: 5.532

6.  Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases.

Authors:  L Palma; N Di Lorenzo; B Guidetti
Journal:  J Neurosurg       Date:  1978-12       Impact factor: 5.115

7.  On the presence of Ia-positive endothelial cells and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation.

Authors:  U Traugott; L C Scheinberg; C S Raine
Journal:  J Neuroimmunol       Date:  1985-04       Impact factor: 3.478

8.  [Frequency and significance of lymphoplasmocyte infiltration in human gliomas (author's transl)].

Authors:  D Schiffer; G Croveri; C Pautasso
Journal:  Tumori       Date:  1974 May-Jun

9.  Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity.

Authors:  P S Steeg; R N Moore; H M Johnson; J J Oppenheim
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

10.  Lymphoreticular cells in human brain tumours and in normal brain.

Authors:  J P Phillips; O Eremin; J R Anderson
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

View more
  63 in total

1.  Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

Authors:  B Frankel; S L Longo; G W Canute
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 3.  Is HCMV a tumor promoter?

Authors:  Liliana Soroceanu; Charles S Cobbs
Journal:  Virus Res       Date:  2010-10-29       Impact factor: 3.303

4.  Immunophenotypic analysis of infiltrating leukocytes and microglia in an experimental rat glioma.

Authors:  T Morioka; T Baba; K L Black; W J Streit
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

5.  Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism.

Authors:  Vladimir V Didenko; Hop N Ngo; Candace Minchew; David S Baskin
Journal:  J Neurosurg       Date:  2002-03       Impact factor: 5.115

6.  The mononuclear cell infiltrate compared with survival in high-grade astrocytomas.

Authors:  M L Rossi; N R Jones; E Candy; J A Nicoll; J S Compton; J T Hughes; M M Esiri; T H Moss; F F Cruz-Sanchez; H B Coakham
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

7.  Immunocytochemical study of the cellular immune response in meningiomas.

Authors:  M L Rossi; F Cruz Sanchez; J T Hughes; M M Esiri; H B Coakham
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

Review 8.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

9.  A Glioblastoma Genomics Primer for Clinicians.

Authors:  John D Patterson; Thidathip Wongsurawat; Analiz Rodriguez
Journal:  Med Res Arch       Date:  2020-02-21

Review 10.  Antibody-based immunotherapy for malignant glioma.

Authors:  Patrick C Gedeon; Katherine A Riccione; Peter E Fecci; John H Sampson
Journal:  Semin Oncol       Date:  2014-06-12       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.